622 related articles for article (PubMed ID: 36128715)
1. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.
L'Hôte V; Mann C; Thuret JY
Open Biol; 2022 Sep; 12(9):220171. PubMed ID: 36128715
[TBL] [Abstract][Full Text] [Related]
2. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics.
Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
FEBS J; 2023 Mar; 290(5):1362-1383. PubMed ID: 35015337
[TBL] [Abstract][Full Text] [Related]
3. Discovering small-molecule senolytics with deep neural networks.
Wong F; Omori S; Donghia NM; Zheng EJ; Collins JJ
Nat Aging; 2023 Jun; 3(6):734-750. PubMed ID: 37142829
[TBL] [Abstract][Full Text] [Related]
4. Targeting cellular senescence in metabolic disease.
Palmer AK; Tchkonia T; Kirkland JL
Mol Metab; 2022 Dec; 66():101601. PubMed ID: 36116755
[TBL] [Abstract][Full Text] [Related]
5. Senescent Cells: A Therapeutic Target in Cardiovascular Diseases.
Suda M; Paul KH; Minamino T; Miller JD; Lerman A; Ellison-Hughes GM; Tchkonia T; Kirkland JL
Cells; 2023 May; 12(9):. PubMed ID: 37174697
[TBL] [Abstract][Full Text] [Related]
6. Chemical Strategies for the Detection and Elimination of Senescent Cells.
García-Fleitas J; García-Fernández A; Martí-Centelles V; Sancenón F; Bernardos A; Martínez-Máñez R
Acc Chem Res; 2024 May; 57(9):1238-1253. PubMed ID: 38604701
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.
Al-Mansour F; Alraddadi A; He B; Saleh A; Poblocka M; Alzahrani W; Cowley S; Macip S
Aging (Albany NY); 2023 Mar; 15(7):2373-2394. PubMed ID: 36988504
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.
Le HH; Cinaroglu SS; Manalo EC; Ors A; Gomes MM; Duan Sahbaz B; Bonic K; Origel Marmolejo CA; Quentel A; Plaut JS; Kawashima TE; Ozdemir ES; Malhotra SV; Ahiska Y; Sezerman U; Bayram Akcapinar G; Saldivar JC; Timucin E; Fischer JM
EBioMedicine; 2021 Nov; 73():103646. PubMed ID: 34689087
[TBL] [Abstract][Full Text] [Related]
9. Senolytics and the compression of late-life mortality.
Kowald A; Kirkwood TBL
Exp Gerontol; 2021 Nov; 155():111588. PubMed ID: 34637949
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration.
Richardson M; Richardson DR
Mol Pharmacol; 2024 Jan; 105(2):64-74. PubMed ID: 38164616
[TBL] [Abstract][Full Text] [Related]
11. Senolysis Enabled by Senescent Cell-Sensitive Bioorthogonal Tetrazine Ligation.
Chang M; Dong Y; Xu H; Cruickshank-Taylor AB; Kozora JS; Behpour B; Wang W
Angew Chem Int Ed Engl; 2024 Feb; 63(9):e202315425. PubMed ID: 38233359
[TBL] [Abstract][Full Text] [Related]
12. A guide to senolytic intervention in neurodegenerative disease.
Lee S; Wang EY; Steinberg AB; Walton CC; Chinta SJ; Andersen JK
Mech Ageing Dev; 2021 Dec; 200():111585. PubMed ID: 34627838
[TBL] [Abstract][Full Text] [Related]
13. Identification of resibufogenin, a component of toad venom, as a novel senolytic compound in vitro and for potential skin rejuvenation in male mice.
Takaya K; Asou T; Kishi K
Biogerontology; 2023 Dec; 24(6):889-900. PubMed ID: 37395866
[TBL] [Abstract][Full Text] [Related]
14. Senotherapeutics in Cancer and HIV.
Sánchez-Díaz L; Espinosa-Sánchez A; Blanco JR; Carnero A
Cells; 2022 Apr; 11(7):. PubMed ID: 35406785
[TBL] [Abstract][Full Text] [Related]
15. Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies.
Khalil R; Diab-Assaf M; Lemaitre JM
Cells; 2023 Mar; 12(6):. PubMed ID: 36980256
[TBL] [Abstract][Full Text] [Related]
16. Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans.
Zhu Y; Prata LGPL; Gerdes EOW; Netto JME; Pirtskhalava T; Giorgadze N; Tripathi U; Inman CL; Johnson KO; Xue A; Palmer AK; Chen T; Schaefer K; Justice JN; Nambiar AM; Musi N; Kritchevsky SB; Chen J; Khosla S; Jurk D; Schafer MJ; Tchkonia T; Kirkland JL
EBioMedicine; 2022 Mar; 77():103912. PubMed ID: 35292270
[TBL] [Abstract][Full Text] [Related]
17. Bone-targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis.
Xing X; Tang Q; Zou J; Huang H; Yang J; Gao X; Xu X; Ma S; Li M; Liang C; Tan L; Liao L; Tian W
Acta Biomater; 2023 Feb; 157():352-366. PubMed ID: 36470392
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic opportunities for senolysis in cardiovascular disease.
Sweeney M; Cook SA; Gil J
FEBS J; 2023 Mar; 290(5):1235-1255. PubMed ID: 35015342
[TBL] [Abstract][Full Text] [Related]
19. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice.
Fielder E; Wan T; Alimohammadiha G; Ishaq A; Low E; Weigand BM; Kelly G; Parker C; Griffin B; Jurk D; Korolchuk VI; von Zglinicki T; Miwa S
Elife; 2022 May; 11():. PubMed ID: 35507395
[TBL] [Abstract][Full Text] [Related]
20. Senotherapeutics for mesenchymal stem cell senescence and rejuvenation.
Wong PF; Dharmani M; Ramasamy TS
Drug Discov Today; 2023 Jan; 28(1):103424. PubMed ID: 36332835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
